Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly.

Abstract

CONTEXT

Reports on the incidence, characteristics, and comorbidity in Asian patients with acromegaly are scarce.

OBJECTIVE

To evaluate the incidence of acromegaly and the risk of comorbidities in East Asia, especially South Korea.

DESIGN

This nationwide population-based cohort study using the Korean Health Insurance Review and Assessment claims database evaluated the incidence of acromegaly, initially diagnosed from 2010 to 2013. We identified comorbidities during, before, and 2 years after diagnosis. Acromegaly and control cases (718 and 7180, respectively) were included in the analysis.

SETTING

A longitudinal case-control study using a nationwide population cohort.

RESULTS

The mean annual incidence rate of acromegaly was 3.57 cases per 1 000 000. Malignancies occurred in 61 patients with acromegaly (8.5%) during the study period and thyroid cancer was the most common malignancy (n = 38). In the acromegaly group, the overall risk of malignancy was higher: hazard ratio (HR), 2.82 (95% confidence interval [CI]: 2.12-3.74). Malignancy risk was more pronounced in females, with increased risk from the prediagnosis period that is sustained until the postdiagnosis period. Prevalence of diabetes mellitus (DM) and heart failure increased significantly in acromegalic patients. Over the entire period, DM developed in 51.1% and 57.0% of male and female acromegalic patients, respectively. Mortality risk was higher (HR 1.65, 95%; CI: 1.13-2.41) and statistically significant in females (HR 1.75, 95%; CI: 1.07-2.84).

CONCLUSION

Comorbidities associated with acromegaly differed by sex in Korean subjects. High malignancy and mortality risk should be considered in female patients when managing acromegaly in Korea.

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine